4503 Astellas Pharma
- 1789.5
- +10.5+0.59%
Astellas Pharma News
Astellas Pharma: Notice Concerning Issuance of Unsecured Ordinary Corporate Bonds
Astellas Pharma: Notice Regarding Issuance of Unsecured Bonds
Astellas Pharma: European Commission Approves Astellas’ PADCEV in Combination with KEYTRUDA for First-Line Treatment of Advanced Urothelial Cancer
Astellas Pharma: Antibody-drug complex PADCEV (enforzumab vedotin) obtained approval in Europe for combination therapy with pembrolizumab for primary treatment of patients with advanced urothelial cancer
Astellas Pharma: China's National Medical Products Administration has approved PADCEV as a treatment for locally advanced or metastatic urothelial carcinoma.
Astellas Pharma: PADCEV (Enfortumab vedotin), an Antibody-Drug Conjugate, has obtained approval in China.
Astellas Pharma: Financial results (Q1/Fiscal Year 2024).
Astellas Pharma: Announcements of individual stock volatility in fair value of contingent consideration.
Astellas Pharma: About recording the fair value change of consideration related to conditions.
Astellas Pharma: Presentation materials for the briefing session (1st quarter of fiscal year 2024).
Astellas Pharma: Supplementary Documents (Q1 FY2024)
Astellas Pharma: Astellas Pharma has received a positive opinion from the CHMP regarding the combination of zolbetuximab and chemotherapy in the treatment of advanced gastric and gastrointestinal cancers.
Astellas Pharma: The European index CHMP has adopted a marketing authorization recommendation for Zolbetuximab.
Astellas Pharma: Astellas Pharma has received a positive opinion from the CHMP for the combination of PADCEV and KEYTRUDA as the first-line treatment for advanced bladder cancer.
Astellas Pharma: European index CHMP has adopted a sales approval recommendation for the combination therapy with Pemprolizumab targeting primary treatment of advanced urothelial cancer patients with PADCEV (enfortumab vedotin).
Astellas Pharma: Corporate Governance Report
Astellas Pharma: China's National Medical Products Administration has approved XTANDI (enzalutamide) for metastatic hormone-sensitive prostate cancer.
Astellas Pharma: XTANDI, a prostate cancer treatment, has obtained approval for additional indications in China.
Astellas Pharma: US Food and Drug Administration acknowledges that Astellas Pharma has re-submitted a biologics license application for zolbetuximab and sets a new date for action
Astellas Pharma: FDA accepts re-application for approval of zolbetuximab
Analysis
Price Target
No Data
